Dyadic International, Inc.

What they do

Dyadic develops and commercializes scalable, non-animal protein-production platforms for life sciences, food and nutrition, and bio-industrial markets, with operations in the United States and the Netherlands. It sells recombinant proteins directly and through OEM distribution partners, and pursues licensing, royalty, and funded development arrangements with third parties. It also continues biopharmaceutical work on its C1 platform under external funding, including Gates Foundation and CEPI-supported programs.

Revenue drivers

• Recombinant protein product sales and OEM distribution — Direct and distributor shipments of recombinant proteins, including transferrin, growth factors, and DNase I; Q2 2026 shipments included six distinct products to IBT Bioservices under an OEM agreement.
• Partner commercialization royalties (Proliant, Fermbox Bio, Inzymes) — Proliant has begun commercializing Albufree DX recombinant human albumin and plans TX and CGT variants; Fermbox Bio has scaled sales of DNase I and transferrin; Inzymes confirmed initial commercial sales of non-animal bovine chymosin, with milestone and royalty potential.
• Funded development and global health collaborations — Development agreements such as the BRIG BIO funded program for recombinant bovine alpha-lactalbumin, plus Gates Foundation-funded RSV and malaria monoclonal antibody work and CEPI/FBS vaccine antigen development, provide third-party funding.

Recent performance

Second quarter 2026 revenue was $961,138, down from $1.2 million in the quarter ended September 30, 2025 and below the $1.1 million reported for the quarter ended March 31, 2026. Full-year revenue was $3.1 million in 2025, down from $3.5 million in 2024, with a net loss of $7.4 million and operating cash outflow of $5.7 million. As of June 30, 2026, the company reported total assets of $6.5 million, total liabilities of $8.9 million, and shareholders' equity of negative $2.4 million, with cash and equivalents of $1.4 million.

Strategy

Management is transitioning Dyadic from a research-driven organization to a commercially focused biotechnology enterprise, rebranded as Dyadic Applied BioSolutions effective August 1, 2025. It is prioritizing non-therapeutic protein markets in life sciences, food and nutrition, and industrial bioprocessing, which it says may offer shorter development timelines and less regulatory complexity than therapeutics. Near-term revenue is being pursued through product sales, OEM distribution arrangements, licensing, and supply agreements, while biopharmaceutical capabilities are advanced mainly with third-party funding. The company reported pilot-scale process improvements that increased recombinant human transferrin productivity by approximately 80%, and it is expanding its precision-fermented dairy protein portfolio through an additional development and commercialization agreement.

Risks

• Going-concern and liquidity — At June 30, 2026, Dyadic had $1.4 million in cash and equivalents against $8.9 million of total liabilities and negative shareholders' equity of $2.4 million, while operating cash flow was negative $5.7 million in 2025.
• Revenue concentration and volatility — Quarterly revenue has swung between roughly $0.6 million and $1.2 million over the last four reported quarters, and full-year 2025 revenue declined to $3.1 million from $3.5 million in 2024.
• Partner-dependent commercialization — Much of the reported commercial progress depends on third parties such as IBT Bioservices, Proliant, Fermbox Bio, Inzymes, and BRIG BIO delivering their own launches and orders, and royalty and milestone revenue is contingent on their success.
• Nasdaq listing-rule exposure — The company disclosed a delisting notice or listing-rule failure event in an 8-K filed June 18, 2026, indicating the stock faces exchange compliance pressure.

Outlook

Management describes accelerating commercialization momentum across product shipments, OEM distribution, and partner-led launches, and says it is driving recurring revenue through strategic partners across life sciences, food and nutrition, and bioindustrial markets. It expects continued validation of the C1 platform through global health and government collaborations, with funding in place to advance the Gates Foundation RSV and malaria monoclonal antibody programs toward preclinical studies. It also points to potential future royalties from Proliant's Albufree portfolio expansion and milestone and royalty potential from an Inzymes second product.